CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Evaluate best-practice approaches employed by comprehensive cancer centers to help minimize the risk of coronavirus infection for patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
  • Individualize the selection of systemic therapy for patients with NSCLC or SCLC to account for the realities of the COVID-19 pandemic and help reduce the potential for SARS-CoV-2 exposure.
  • Appreciate the rationale for and appropriateness of adapting specific lung cancer management and follow-up practices to limit in-person interaction in response to the current need for social distancing.
  • Recall recently presented findings from the TERAVOLT registry and other efforts evaluating the impact of COVID-19 on mortality and other outcomes among patients with lung cancer.
  • Consider expert perspectives and real-world experiences when implementing a plan of care for patients with lung cancer who have been diagnosed with COVID-19.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THESE CME ACTIVITIES
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Leora Horn, MD, MSc
  Ingram Associate Professor of Cancer Research
  Director, Thoracic Oncology Research Program
  Assistant Vice Chairman for Faculty Development
  Vanderbilt University Medical Center
  Nashville, Tennessee
  
  Advisory Committee: Amgen Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Xcovery; Consulting Agreements: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, Xcovery; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Xcovery.
  
  Naiyer A Rizvi, MD
  Price Family Professor of Medicine
  Director, Thoracic Oncology and Phase I Immunotherapeutics
  Division of Hematology/Oncology
  Columbia University Irving Medical Center
  New York, New York
  
  No financial interests or affiliations to disclose.
  
  Lecia V Sequist, MD, MPH
  Director, Center for Innovation in Early Cancer Detection
  Massachusetts General Hospital Cancer Center
  The Landry Family Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Novartis; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group; Patent Pending: In conjunction with Blueprint Medicines.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
  
  Release date: August 2020
  Expiration date: August 2021